Radical investor Starboard is aggressively acquiring shares in Dynatrace (DT.US): moving into the top five shareholders and pushing for a $2.5 billion buyback of shares within three years.
A draft of a letter from a senior management member of activist investor Starboard Value shows that the firm has accumulated a significant stake in artificial intelligence software manufacturer Dynatrace (DT.US).
Radical investor Starboard Value's draft letter from a senior management member shows that the institution has acquired a substantial stake in artificial intelligence software manufacturer Dynatrace (DT.US) and is pushing for strategic changes to help boost its stock price.
In the draft letter intended to be sent to Dynatrace on Tuesday, Starboard management member Peter Feld points out that the company's stock valuation is relatively low compared to peers in the industry.
As a result of this news, Dynatrace's stock price surged 8% in after-hours trading.
Starboard is currently one of the top five shareholders of Dynatrace and has been in private contact with the company's leadership in recent months.
Starboard believes that due to a slowdown in revenue growth and investor concerns about short-term performance, Dynatrace's stock price has been underperforming.
Despite Dynatrace raising its revenue forecast for 2026 from a range of $1.985 billion to $1.995 billion to a range of $2.005 billion to $2.010 billion, its stock price has dropped by over 17% this year.
Starboard suggests that Dynatrace should accelerate its stock buyback plan and recommends that the company repurchase over $2.5 billion in shares over the next three years.
Previously, Dynatrace announced a $1 billion share buyback plan in February.
The main goal of radical investors buying company shares is to influence management and drive changes aimed at boosting stock prices and increasing shareholder value.
Related Articles

IMMUNOTECH-B (06978) suspended trading in the afternoon of April 28th.

GENFLEET-B(02595): The subject, products, and disputed issues related to the letter issued by Rev Med have nothing to do with the company.

RIMAG GROUP (02522) x Yehe Medical Strategic Release of Super Smart CT Brain Imaging Intelligence: from "Image Recognition" to "Image Understanding", medical imaging AI welcomes killer-level applications at the "examination project level".
IMMUNOTECH-B (06978) suspended trading in the afternoon of April 28th.

GENFLEET-B(02595): The subject, products, and disputed issues related to the letter issued by Rev Med have nothing to do with the company.

RIMAG GROUP (02522) x Yehe Medical Strategic Release of Super Smart CT Brain Imaging Intelligence: from "Image Recognition" to "Image Understanding", medical imaging AI welcomes killer-level applications at the "examination project level".






